Abstract: Objective To retrospective analysis summarized the effectiveness and safety of the “triple” conversion therapy regimen combining immune,targeted and local therapy.Methods From February 2019 to June 2023,52 patients with advanced liver cancer from February 2019 to June 2023 in XI,an Jiao Tong university medicine college affiliated 3201 hospital were admitted and received conversion treatment regimens combining sintilimab with bevacizumab and combined with local treatment,analyzed the surgical resection rate and pathological complete response rate (pCR),complete response rate (CR),partial response rate (PR),progression of disease (PD),stable disease (SD),objective response rate (ORR) and disease control rate(DCR).To evaluated the effect of conversion therapy and adverse reactions.Results 21 cases had recived operative resection in the 52 patients with primary liver cancer receiving sintilimab and bevacizumab.The postoperative resection rate was 40.4% (21/52),pCR 42.9% (9/21).The other 31 cases have complete response 5.8%(3/52),PR 25.0%(13/52),PD 11.5%(6/52),SD 17.3%(9/52).The overall objective response rate (ORR) was71.2% (37/52),and the disease control rate (DCR) was 88.5% (46/52).Adverse reactions manifest as Grade 1-2 skin-related damage primarily affecting the epidermis.Conclusion For patients with potentially resectable primary liver cancer in middle and advanced stage,the “triple” conversion therapy with sintilimab combined with bevacizumab as systematic treatment and combined with local therapy can achieve good conversion treatment effect with controllable safety.

Key words: liver cancer, conversion therapy, triple scheme, retrospective analysis